Leber Congenital Amaurosis 10 clinical trials at UCSF

1 research study open to eligible people

Leber congenital amaurosis 10 is a disease that leads to severe loss of vision due to gene mutations. At UCSF, trials are underway evaluating Sepofarsen as a potential treatment. These studies include placebo controls to reliably measure changes in eyesight between treated and untreated eyes.

Showing trials for

  • Sepofarsen in Subjects With Leber Congenital Amaurosis (LCA) Type 10 (HYPERION)

    open to eligible people ages 6 years and up

    The purpose of this double-masked, randomized, placebo-controlled, paired-eye study is to evaluate the efficacy, safety and tolerability of Sepofarsen in subjects with Leber Congenital Amaurosis (LCA) due to the c.2991+1655A>G (p.Cys998X) mutation in the CEP290.

    San Francisco, California and other locations

Last updated: